-
1
-
-
0027941369
-
Intensive postremission chemotherapy in adults with acute myeloid leukemia
-
Mayer RJ, Davis RB, Schiffer CA et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med. 331(14), 896-903 (1994
-
(1994)
N. Engl. J. Med
, vol.331
, Issue.14
, pp. 896-903
-
-
Mayer, R.J.1
Davis, R.B.2
Schiffer, C.A.3
-
2
-
-
70349451999
-
High-dose daunorubicin in older patients with acute myeloid leukemia
-
Löwenberg B, Ossenkoppele GJ, van Putten W et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N. Engl. J. Med. 361(13), 1235-1248 (2009
-
(2009)
N. Engl. J. Med
, vol.361
, Issue.13
, pp. 1235-1248
-
-
Löwenberg, B.1
Ossenkoppele, G.J.2
Van Putten, W.3
-
3
-
-
84872087060
-
Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
-
Löwenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 121(1), 26-28 (2013
-
(2013)
Blood
, vol.121
, Issue.1
, pp. 26-28
-
-
Löwenberg, B.1
-
4
-
-
84873335475
-
Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older
-
Gardin C, Chevret S, Pautas C et al. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. J. Clin. Oncol. 31(3), 321-327 (2013
-
(2013)
J. Clin. Oncol
, vol.31
, Issue.3
, pp. 321-327
-
-
Gardin, C.1
Chevret, S.2
Pautas, C.3
-
5
-
-
0025100777
-
Graft-versus-leukemia reactions after bone marrow transplantation
-
Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3), 555-562 (1990
-
(1990)
Blood
, vol.75
, Issue.3
, pp. 555-562
-
-
Horowitz, M.M.1
Gale, R.P.2
Sondel, P.M.3
-
6
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
-
(2010)
N. Engl. J. Med
, vol.363
, Issue.8
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
-
7
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD 1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD 1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012
-
(2012)
N. Engl. J. Med
, vol.366
, Issue.26
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
-
8
-
-
69049089548
-
The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research
-
Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15(17), 5323-5337 (2009
-
(2009)
Clin. Cancer Res
, vol.15
, Issue.17
, pp. 5323-5337
-
-
Cheever, M.A.1
Allison, J.P.2
Ferris, A.S.3
-
9
-
-
84867685827
-
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
-
Landsberg J, Kohlmeyer J, Renn M et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490(7420), 412-416 (2012
-
(2012)
Nature
, vol.490
, Issue.7420
, pp. 412-416
-
-
Landsberg, J.1
Kohlmeyer, J.2
Renn, M.3
-
10
-
-
84860436621
-
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: A Phase 1 dose-escalation trial
-
van den Eertwegh AJM, Versluis J, van den Berg HP et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: A Phase 1 dose-escalation trial. Lancet Oncol. 13(5), 509-517 (2012
-
(2012)
Lancet Oncol
, vol.13
, Issue.5
, pp. 509-517
-
-
Van Den Eertwegh, A.J.M.1
Versluis, J.2
Van Den Berg, H.P.3
-
11
-
-
0034614886
-
The induction of tolerance by dendritic cells that have captured apoptotic cells
-
Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 191(3), 411-416 (2000
-
(2000)
J. Exp. Med
, vol.191
, Issue.3
, pp. 411-416
-
-
Steinman, R.M.1
Turley, S.2
Mellman, I.3
Inaba, K.4
-
12
-
-
77956255766
-
Find-me and eat-me signals in apoptotic cell clearance: Progress and conundrums
-
Ravichandran KS. Find-me and eat-me signals in apoptotic cell clearance: Progress and conundrums. J. Exp. Med. 207(9), 1807-1817 (2010
-
(2010)
J. Exp. Med
, vol.207
, Issue.9
, pp. 1807-1817
-
-
Ravichandran, K.S.1
-
13
-
-
80755180853
-
Beginnings of a good apoptotic meal: The find-me and eat-me signaling pathways
-
Ravichandran KS. Beginnings of a good apoptotic meal: The find-me and eat-me signaling pathways. Immunity 35(4), 445-455 (2011
-
(2011)
Immunity
, vol.35
, Issue.4
, pp. 445-455
-
-
Ravichandran, K.S.1
-
14
-
-
77956941695
-
Decrease of sialic acid residues as an eat-me signal on the surface of apoptotic lymphocytes
-
Meesmann HM, Fehr EM, Kierschke S et al. Decrease of sialic acid residues as an eat-me signal on the surface of apoptotic lymphocytes. J. Cell Sci. 123(Pt 19), 3347-3356 (2010
-
(2010)
J. Cell Sci
, vol.123
, Issue.PART 19
, pp. 3347-3356
-
-
Meesmann, H.M.1
Fehr, E.M.2
Kierschke, S.3
-
15
-
-
3543053363
-
Immature dendritic cells phagocytose apoptotic cells via avb5 CD36 and cross-present antigens to cytotoxic T lymphocytes
-
Albert ML, Pearce SFA, Francisco LM et al. Immature dendritic cells phagocytose apoptotic cells via avb5 CD36 and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188(7), 1359-1368 (1998
-
(1998)
J. Exp. Med
, vol.188
, Issue.7
, pp. 1359-1368
-
-
Albert, M.L.1
Pearce, S.F.A.2
Francisco, L.M.3
-
16
-
-
77949881623
-
LOX-1 as a natural IFN a-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells
-
Parlato S, Romagnoli G, Spadaro F et al. LOX-1 as a natural IFN a-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells. Blood 115(8), 1554-1563 (2010
-
(2010)
Blood
, vol.115
, Issue.8
, pp. 1554-1563
-
-
Parlato, S.1
Romagnoli, G.2
Spadaro, F.3
-
17
-
-
0034091785
-
Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response
-
Russo V, Tanzarella S, Dalerba P et al. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc. Natl Acad. Sci. USA 97(5), 2185-2190 (2000
-
(2000)
Proc. Natl Acad. Sci. USA
, vol.97
, Issue.5
, pp. 2185-2190
-
-
Russo, V.1
Tanzarella, S.2
Dalerba, P.3
-
18
-
-
0033565513
-
Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines
-
Henry F, Boisteau O, Bretaudeau L, Lieubeau B, Meflah K, Grégoire M. Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res. 59(14), 3329-3332 (1999
-
(1999)
Cancer Res
, vol.59
, Issue.14
, pp. 3329-3332
-
-
Henry, F.1
Boisteau, O.2
Bretaudeau, L.3
Lieubeau, B.4
Meflah, K.5
Grégoire, M.6
-
19
-
-
0031798137
-
Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells
-
Inaba K, Turley S, Yamaide F et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J. Exp. Med. 188(11), 2163-2173 (1998
-
(1998)
J. Exp. Med
, vol.188
, Issue.11
, pp. 2163-2173
-
-
Inaba, K.1
Turley, S.2
Yamaide, F.3
-
20
-
-
1542373657
-
Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis
-
Wilson NS, El-Sukkari D, Villadangos JA. Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis. Blood 103(6), 2187-2195 (2004
-
(2004)
Blood
, vol.103
, Issue.6
, pp. 2187-2195
-
-
Wilson, N.S.1
El-Sukkari, D.2
Villadangos, J.A.3
-
21
-
-
77953417284
-
Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia
-
van den Ancker W, van Luijn MM, Westers TM et al. Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia. Immunotherapy 2(1), 69-83 (2010
-
(2010)
Immunotherapy
, vol.2
, Issue.1
, pp. 69-83
-
-
Van Den Ancker, W.1
Van Luijn, M.M.2
Westers, T.M.3
-
22
-
-
0037268105
-
Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia
-
Westers TM, Stam AG, Scheper RJ et al. Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia. Cell 52(1), 17-27 (2003
-
(2003)
Cell
, vol.52
, Issue.1
, pp. 17-27
-
-
Westers, T.M.1
Stam, A.G.2
Scheper, R.J.3
-
23
-
-
78649479185
-
Sirna silencing of PD L1 and PD L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells
-
Hobo W, Maas F, Adisty N et al. siRNA silencing of PD L1 and PD L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells. Blood 116(22), 4501-4511 (2010
-
(2010)
Blood
, vol.116
, Issue.22
, pp. 4501-4511
-
-
Hobo, W.1
Maas, F.2
Adisty, N.3
-
24
-
-
34848827168
-
Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-Antigen positive tumors
-
Tamir A, Basagila E, Kagahzian A et al. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-Antigen positive tumors. Cell 56(12), 2003-2016 (2007
-
(2007)
Cell
, vol.56
, Issue.12
, pp. 2003-2016
-
-
Tamir, A.1
Basagila, E.2
Kagahzian, A.3
-
25
-
-
73349131696
-
Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients
-
Toh HC, Wang WW, Chia WK et al. Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients. Clin. Cancer Res. 15(24), 7726-7736 (2009
-
(2009)
Clin. Cancer Res
, vol.15
, Issue.24
, pp. 7726-7736
-
-
Toh, H.C.1
Wang, W.W.2
Chia, W.K.3
-
26
-
-
77958575663
-
Harnessing naturally occurring tumor immunity: A clinical vaccine trial in prostate cancer
-
Frank MO, Kaufman J, Tian S et al. Harnessing naturally occurring tumor immunity: A clinical vaccine trial in prostate cancer. PLoS ONE 5(9), e12367 (2010
-
(2010)
PLoS ONE
, vol.5
, Issue.9
-
-
Frank, M.O.1
Kaufman, J.2
Tian, S.3
-
27
-
-
79952635146
-
Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia
-
Kitawaki T, Kadowaki N, Fukunaga K et al. Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia. Exp. Hematol. 39(4), 424-433 e2 (2011
-
(2011)
Exp. Hematol
, vol.39
, Issue.4
-
-
Kitawaki, T.1
Kadowaki, N.2
Fukunaga, K.3
-
28
-
-
43749119376
-
Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response
-
Hus I, Schmitt M, Tabarkiewicz J et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia 22(5), 1007-1017 (2008
-
(2008)
Leukemia
, vol.22
, Issue.5
, pp. 1007-1017
-
-
Hus, I.1
Schmitt, M.2
Tabarkiewicz, J.3
-
29
-
-
0018970399
-
Results of randomized trials of immunotherapy for acute leukemia
-
Vogler W. Results of randomized trials of immunotherapy for acute leukemia. Cell 9(1-2), 15-21 (1980
-
(1980)
Cell
, vol.9
, Issue.1-2
, pp. 15-21
-
-
Vogler, W.1
-
30
-
-
33846057130
-
Calreticulin exposure dictates the immunogenicity of cancer cell death
-
Obeid M, Tesniere A, Ghiringhelli F et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13(1), 54-61 (2007
-
(2007)
Nat. Med
, vol.13
, Issue.1
, pp. 54-61
-
-
Obeid, M.1
Tesniere, A.2
Ghiringhelli, F.3
-
31
-
-
84871717972
-
Calreticulin in the immune system: Ins and outs
-
Raghavan M, Wijeyesakere SJ, Peters LR, Del Cid N. Calreticulin in the immune system: Ins and outs. Trends Immunol. 34(1), 13-21 (2013
-
(2013)
Trends Immunol
, vol.34
, Issue.1
, pp. 13-21
-
-
Raghavan, M.1
Wijeyesakere, S.J.2
Peters, L.R.3
Del Cid, N.4
-
32
-
-
37349051718
-
Molecular characteristics of immunogenic cancer cell death
-
Tesniere A, Panaretakis T, Kepp O et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 15(1), 3-12 (2008
-
(2008)
Cell Death Differ
, vol.15
, Issue.1
, pp. 3-12
-
-
Tesniere, A.1
Panaretakis, T.2
Kepp, O.3
-
33
-
-
0032779055
-
Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity
-
Dunussi-Joannopoulos K, Runyon K, Erickson J, Schaub RG, Hawley RG, Leonard JP. Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity. Blood 94(12), 4263-4273 (1999
-
(1999)
Blood
, vol.94
, Issue.12
, pp. 4263-4273
-
-
Dunussi-Joannopoulos, K.1
Runyon, K.2
Erickson, J.3
Schaub, R.G.4
Hawley, R.G.5
Leonard, J.P.6
-
34
-
-
34447123763
-
Granulocyte macrophage colony-stimulating factor -secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
-
Small EJ, Sacks N, Nemunaitis J et al. Granulocyte macrophage colony-stimulating factor -secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 13(13), 3883-3891 (2007
-
(2007)
Clin. Cancer Res
, vol.13
, Issue.13
, pp. 3883-3891
-
-
Small, E.J.1
Sacks, N.2
Nemunaitis, J.3
-
35
-
-
0034689496
-
Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line
-
Osanto S, Schiphorst PP, Weijl NI et al. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum. Gene Ther. 11(5), 739-750 (2000
-
(2000)
Hum. Gene Ther
, vol.11
, Issue.5
, pp. 739-750
-
-
Osanto, S.1
Schiphorst, P.P.2
Weijl, N.I.3
-
36
-
-
0036181209
-
Vaccination of stage IV patients with allogeneic IL 4-or IL 2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells
-
Maio M, Fonsatti E, Lamaj E et al. Vaccination of stage IV patients with allogeneic IL 4-or IL 2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cell 51(1), 9-14 (2002
-
(2002)
Cell
, vol.51
, Issue.1
, pp. 9-14
-
-
Maio, M.1
Fonsatti, E.2
Lamaj, E.3
-
37
-
-
0033544933
-
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells
-
Arienti F, Belli F, Napolitano F et al. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum. Gene Ther. 10, 2907-2916 (1999
-
(1999)
Hum. Gene Ther
, vol.10
, pp. 2907-2916
-
-
Arienti, F.1
Belli, F.2
Napolitano, F.3
-
38
-
-
0030820018
-
A Phase I clinical trial of immunotherapy with interferon-g gene-modified autologous melanoma cells: Monitoring the humoral immune response
-
Abdel-Wahab Z, Weltz C, Hester D et al. A Phase I clinical trial of immunotherapy with interferon-g gene-modified autologous melanoma cells: Monitoring the humoral immune response. Cancer 80(3), 401-412 (1997
-
(1997)
Cancer
, vol.80
, Issue.3
, pp. 401-412
-
-
Abdel-Wahab, Z.1
Weltz, C.2
Hester, D.3
-
39
-
-
0031895957
-
Vaccination with IL 12 gene-modified autologous melanoma cells: Preclinical results and a first clinical Phase I study
-
Sun Y, Jurgovsky K, Möller P et al. Vaccination with IL 12 gene-modified autologous melanoma cells: Preclinical results and a first clinical Phase I study. Gene Ther. 5(4), 481-490 (1998
-
(1998)
Gene Ther
, vol.5
, Issue.4
, pp. 481-490
-
-
Sun, Y.1
Jurgovsky, K.2
Möller, P.3
-
40
-
-
33845721818
-
GM CSF gene-modifed cancer cell immunotherapies: Of mice and men
-
Hege KM, Jooss K, Pardoll D. GM CSF gene-modifed cancer cell immunotherapies: Of mice and men. Int. Rev. Immunol. 25(5-6), 321-352 (2006
-
(2006)
Int. Rev. Immunol
, vol.25
, Issue.5-6
, pp. 321-352
-
-
Hege, K.M.1
Jooss, K.2
Pardoll, D.3
-
41
-
-
70349446800
-
Biologic activity of irradiated, autologous, GM CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation
-
Ho VT, Vanneman M, Kim H et al. Biologic activity of irradiated, autologous, GM CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc. Natl Acad. Sci. USA 106(37), 15825-15830 (2009
-
(2009)
Proc. Natl Acad. Sci. USA
, vol.106
, Issue.37
, pp. 15825-15830
-
-
Ho, V.T.1
Vanneman, M.2
Kim, H.3
-
42
-
-
70349242210
-
Granulocyte-macrophage colony-stimulating factor (GM CSF secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)
-
Borrello IM, Levitsky HI, Stock W et al. Granulocyte-macrophage colony-stimulating factor (GM CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 114(9), 1736-1745 (2009
-
(2009)
Blood
, vol.114
, Issue.9
, pp. 1736-1745
-
-
Borrello, I.M.1
Levitsky, H.I.2
Stock, W.3
-
43
-
-
18144372419
-
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of thefirst Phase I clinical trial
-
Escudier B, Dorval T, Chaput N et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: Results of thefirst Phase I clinical trial. J. Transl. Med. 3(1), 10 (2005
-
(2005)
J. Transl. Med
, vol.3
, Issue.1
, pp. 10
-
-
Escudier, B.1
Dorval, T.2
Chaput, N.3
-
44
-
-
52049102433
-
Efficient cross-presentation depends on autophagy in tumor cells
-
Li Y, Wang LX, Yang G, Hao F, Urba WJ, Hu HM. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res. 68(17), 6889-6895 (2008
-
(2008)
Cancer Res
, vol.68
, Issue.17
, pp. 6889-6895
-
-
Li, Y.1
Wang, L.X.2
Yang, G.3
Hao, F.4
Urba, W.J.5
Hu, H.M.6
-
45
-
-
81255138298
-
Tumor-derived autophagosome vaccine: Mechanism of cross-presentation and therapeutic efficacy
-
Li Y, Wang LX, Pang P et al. Tumor-derived autophagosome vaccine: Mechanism of cross-presentation and therapeutic efficacy. Clin. Cancer Res.17(22), 7047-7057 (2011
-
(2011)
Clin. Cancer Res
, vol.17
, Issue.22
, pp. 7047-7057
-
-
Li, Y.1
Wang, L.X.2
Pang, P.3
-
46
-
-
82455192402
-
DRiPs solidify: Progress in understanding endogenous MHC class I antigen processing
-
Yewdell JW. DRiPs solidify: Progress in understanding endogenous MHC class I antigen processing. Trends Immunol. 32(11), 548-558 (2011
-
(2011)
Trends Immunol
, vol.32
, Issue.11
, pp. 548-558
-
-
Yewdell, J.W.1
-
47
-
-
68049091014
-
Mouse dendritic cells matured by ingestion of apoptotic blebs induce T cells to produce interleukin-17
-
Fransen JH, Hilbrands LB, Ruben J et al. Mouse dendritic cells matured by ingestion of apoptotic blebs induce T cells to produce interleukin-17. Arthritis Rheum. 60(8), 2304-2313 (2009
-
(2009)
Arthritis Rheum
, vol.60
, Issue.8
, pp. 2304-2313
-
-
Fransen, J.H.1
Hilbrands, L.B.2
Ruben, J.3
-
48
-
-
0028091194
-
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
-
Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464), 645-648 (1994
-
(1994)
Nature
, vol.367
, Issue.6464
, pp. 645-648
-
-
Lapidot, T.1
Sirard, C.2
Vormoor, J.3
-
49
-
-
0030789242
-
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
-
Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3(7), 730-737 (1997
-
(1997)
Nat. Med
, vol.3
, Issue.7
, pp. 730-737
-
-
Bonnet, D.1
Dick, J.E.2
-
50
-
-
33749436571
-
Searching for leukemia stem cells -not yet the end of the road?
-
Jordan CT. Searching for leukemia stem cells -not yet the end of the road? Cancer Cell 10(4), 253-254 (2006
-
(2006)
Cancer Cell
, vol.10
, Issue.4
, pp. 253-254
-
-
Jordan, C.T.1
-
51
-
-
58149380742
-
Stem cell concepts renew cancer research
-
Dick JE. Stem cell concepts renew cancer research. Blood 112(13), 4793-4807 (2008
-
(2008)
Blood
, vol.112
, Issue.13
, pp. 4793-4807
-
-
Dick, J.E.1
-
52
-
-
25144433295
-
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival
-
van Rhenen A, Feller N, Kelder A et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin. Cancer Res. 11(18), 6520-6527 (2005
-
(2005)
Clin. Cancer Res
, vol.11
, Issue.18
, pp. 6520-6527
-
-
Van Rhenen, A.1
Feller, N.2
Kelder, A.3
-
53
-
-
58049211689
-
Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia
-
Moshaver B, van Rhenen A, Kelder A et al. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells 26(12), 3059-3067 (2008
-
(2008)
Stem Cells
, vol.26
, Issue.12
, pp. 3059-3067
-
-
Moshaver, B.1
Van Rhenen, A.2
Kelder, A.3
-
54
-
-
79955438869
-
SALL4, a stem cell factor, affects the side population by regulation of the ATP-binding cassette drug transport genes
-
Jeong HW, Cui W, Yang Y et al. SALL4, a stem cell factor, affects the side population by regulation of the ATP-binding cassette drug transport genes. PLoS ONE 6(4), e18372 (2011
-
(2011)
PLoS ONE
, vol.6
, Issue.4
-
-
Jeong, H.W.1
Cui, W.2
Yang, Y.3
-
55
-
-
0035883060
-
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia
-
Wulf GG, Wang RY, Kuehnle I et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98(4), 1166-1173 (2001
-
(2001)
Blood
, vol.98
, Issue.4
, pp. 1166-1173
-
-
Wulf, G.G.1
Wang, R.Y.2
Kuehnle, I.3
-
56
-
-
84859854912
-
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia
-
Gerber JM, Smith BD, Ngwang B et al. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood 119(15), 3571-3577 (2012
-
(2012)
Blood
, vol.119
, Issue.15
, pp. 3571-3577
-
-
Gerber, J.M.1
Smith, B.D.2
Ngwang, B.3
-
57
-
-
78649686241
-
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells
-
Kikushige Y, Shima T, Takayanagi S et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 7(6), 708-717 (2010
-
(2010)
Cell Stem Cell
, vol.7
, Issue.6
, pp. 708-717
-
-
Kikushige, Y.1
Shima, T.2
Takayanagi, S.3
-
58
-
-
34948839959
-
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells
-
van Rhenen A, van Dongen GA, Kelder A et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 110(7), 2659-2666 (2007
-
(2007)
Blood
, vol.110
, Issue.7
, pp. 2659-2666
-
-
Van Rhenen, A.1
Van Dongen, G.A.2
Kelder, A.3
-
59
-
-
0033815950
-
The interleukin-3 receptor a chain is a unique marker for human acute myelogenous leukemia stem cells
-
Jordan CT, Upchurch D, Szilvassy SJ et al. The interleukin-3 receptor a chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14(10), 1777-1784 (2000
-
(2000)
Leukemia
, vol.14
, Issue.10
, pp. 1777-1784
-
-
Jordan, C.T.1
Upchurch, D.2
Szilvassy, S.J.3
-
60
-
-
34547415968
-
CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia
-
Hosen N, Park CY, Tatsumi N et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc. Natl Acad. Sci. USA 104(26), 11008-11013 (2007
-
(2007)
Proc. Natl Acad. Sci. USA
, vol.104
, Issue.26
, pp. 11008-11013
-
-
Hosen, N.1
Park, C.Y.2
Tatsumi, N.3
-
61
-
-
84864255882
-
The origin and evolution of mutations in acute myeloid leukemia
-
Welch JS, Ley TJ, Link DC et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150(2), 264-278 (2012
-
(2012)
Cell
, vol.150
, Issue.2
, pp. 264-278
-
-
Welch, J.S.1
Ley, T.J.2
Link, D.C.3
-
62
-
-
84862776906
-
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
-
Ding L, Ley TJ, Larson DE et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481(7382), 506-510 (2012
-
(2012)
Nature
, vol.481
, Issue.7382
, pp. 506-510
-
-
Ding, L.1
Ley, T.J.2
Larson, D.E.3
-
63
-
-
33748320471
-
New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents
-
Tallman MS. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematology 2005(1), 143-150 (2005
-
(2005)
Hematology
, vol.2005
, Issue.1
, pp. 143-150
-
-
Tallman, M.S.1
-
64
-
-
84874403639
-
Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex
-
Gao C, Dimitrov T, Yong KJ et al. Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex. Blood 121(8), 1413-1421 (2013
-
(2013)
Blood
, vol.121
, Issue.8
, pp. 1413-1421
-
-
Gao, C.1
Dimitrov, T.2
Yong, K.J.3
-
65
-
-
80053542413
-
Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8+ T cells
-
Visus C, Wang Y, Lozano-Leon A et al. Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8+ T cells. Clin. Cancer Res. 17(19), 6174-6184 (2011
-
(2011)
Clin. Cancer Res
, vol.17
, Issue.19
, pp. 6174-6184
-
-
Visus, C.1
Wang, Y.2
Lozano-Leon, A.3
-
66
-
-
80052468964
-
Stem cell gene expression programs influence clinical outcome in human leukemia
-
Eppert K, Takenaka K, Lechman ER et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17(9), 1086-1093 (2011
-
(2011)
Nat. Med
, vol.17
, Issue.9
, pp. 1086-1093
-
-
Eppert, K.1
Takenaka, K.2
Lechman, E.R.3
-
67
-
-
69849104865
-
The leukemic stem cell niche: Current concepts and therapeutic opportunities
-
Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: Current concepts and therapeutic opportunities. Blood 114(6), 1150-1157 (2009
-
(2009)
Blood
, vol.114
, Issue.6
, pp. 1150-1157
-
-
Lane, S.W.1
Scadden, D.T.2
Gilliland, D.G.3
-
69
-
-
35948984135
-
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region
-
Ishikawa F, Yoshida S, Saito Y et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol. 25(11), 1315-1321 (2007
-
(2007)
Nat. Biotechnol
, vol.25
, Issue.11
, pp. 1315-1321
-
-
Ishikawa, F.1
Yoshida, S.2
Saito, Y.3
-
70
-
-
58249100053
-
CXCR4 antagonists: Targeting the microenvironment in leukemia and other cancers
-
Burger JA, Peled A. CXCR4 antagonists: Targeting the microenvironment in leukemia and other cancers. Leukemia 23(1), 43-52 (2009
-
(2009)
Leukemia
, vol.23
, Issue.1
, pp. 43-52
-
-
Burger, J.A.1
Peled, A.2
-
71
-
-
84878411869
-
Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary co-cultures by altering the myeloid microenvironment
-
Schulz A, Dürr C, Zenz T et al. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary co-cultures by altering the myeloid microenvironment. Blood 121(13), 2503-2511 (2013
-
(2013)
Blood
, vol.121
, Issue.13
, pp. 2503-2511
-
-
Schulz, A.1
Dürr, C.2
Zenz, T.3
-
72
-
-
84876422526
-
Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence
-
Takeishi S, Matsumoto A, Onoyama I, Naka K, Hirao A, Nakayama KI. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell 23(3), 347-361 (2013
-
(2013)
Cancer Cell
, vol.23
, Issue.3
, pp. 347-361
-
-
Takeishi, S.1
Matsumoto, A.2
Onoyama, I.3
Naka, K.4
Hirao, A.5
Nakayama, K.I.6
-
73
-
-
0141461414
-
Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia
-
Matsunaga T, Takemoto N, Sato T et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med. 9(9), 1158-1165 (2003
-
(2003)
Nat. Med
, vol.9
, Issue.9
, pp. 1158-1165
-
-
Matsunaga, T.1
Takemoto, N.2
Sato, T.3
-
74
-
-
84868193304
-
A safety run-in and randomized Phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306
-
Nabors LB, Mikkelsen T, Hegi ME et al. A safety run-in and randomized Phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 118(22), 5601-5607 (2012
-
(2012)
Cancer
, vol.118
, Issue.22
, pp. 5601-5607
-
-
Nabors, L.B.1
Mikkelsen, T.2
Hegi, M.E.3
-
75
-
-
79960898228
-
Elevated frequencies of CD4+ CD25+ CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia
-
Shenghui Z, Yixiang H, Jianbo W et al. Elevated frequencies of CD4+ CD25+ CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int. J. Cancer 129(6), 1373-1381 (2011
-
(2011)
Int. J. Cancer
, vol.129
, Issue.6
, pp. 1373-1381
-
-
Shenghui, Z.1
Yixiang, H.2
Jianbo, W.3
-
76
-
-
66149179122
-
Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia
-
Szczepanski MJ, Szajnik M, Czystowska M et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin. Cancer Res. 15(10), 3325-3332 (2009
-
(2009)
Clin. Cancer Res
, vol.15
, Issue.10
, pp. 3325-3332
-
-
Szczepanski, M.J.1
Szajnik, M.2
Czystowska, M.3
-
77
-
-
84873192230
-
Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in sokal high risk chronic myeloid leukemia
-
Christiansson L, Söderlund S, Svensson E et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in sokal high risk chronic myeloid leukemia. PLoS ONE 8(1), e55818 (2013
-
(2013)
PLoS ONE
, vol.8
, Issue.1
-
-
Christiansson, L.1
Söderlund, S.2
Svensson, E.3
-
78
-
-
84875511757
-
Tumor necrosis factor-A blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation
-
Sade-Feldman M, Kanterman J, Ish-Shalom E, Elnekave M, Horwitz E, Baniyash M. Tumor necrosis factor-A blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 38(3), 541-554 (2013
-
(2013)
Immunity
, vol.38
, Issue.3
, pp. 541-554
-
-
Sade-Feldman, M.1
Kanterman, J.2
Ish-Shalom, E.3
Elnekave, M.4
Horwitz, E.5
Baniyash, M.6
-
79
-
-
84863924314
-
Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: A current perspective
-
Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: A current perspective. Cancer Res. 72(14), 3439-3444 (2012
-
(2012)
Cancer Res
, vol.72
, Issue.14
, pp. 3439-3444
-
-
Le, D.T.1
Jaffee, E.M.2
-
80
-
-
77957723967
-
Upregulation of Tim-3 and PD 1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
-
Fourcade J, Sun Z, Benallaoua M et al. Upregulation of Tim-3 and PD 1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 207(10), 2175-2186 (2010
-
(2010)
J. Exp. Med
, vol.207
, Issue.10
, pp. 2175-2186
-
-
Fourcade, J.1
Sun, Z.2
Benallaoua, M.3
|